Knight Therapeutics Inc. faced a challenging trading session, resulting in a notable decline.
In yesterday's trading session, Knight Therapeutics Inc. (GUD.TO) experienced a significant drop, closing down by 4.61%. This decline raises questions about the company's current market position and investor sentiment.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeAdvertisement
Market cap
$958.74M
P/E
162.7x
52W high
$10.17
52W low
$5.66
1W change
-5.39%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 9.7% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.21
+9.7% Upside
Current Price
C$9.31
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
29.3%
Annualized
90-Day Vol
31.7%
Annualized
Trend (90d)
+38.7%
Annualized drift
90d Mean
C$10.69
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.75 | C$8.81 – C$10.79 |
| 60 trading days | C$10.21 | C$8.85 – C$11.78 |
| 90 trading days | C$10.69 | C$8.97 – C$12.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should remain cautious as Knight Therapeutics struggles to maintain momentum amidst fluctuating market conditions.
Knight Therapeutics Inc. Down 4.61%
The stock's decline to CA$9.31 indicates a potential shift in investor sentiment.
Bull case
Knight Therapeutics recently reported record-high quarterly revenues and adjusted EBITDA for Q3 2025. This suggests there’s potential for future growth, which could be a positive sign for investors.
Bear case
However, the stock's recent performance reflects concerns about sustainability and market confidence, especially following its acquisition of Paladin. Investors are clearly weighing these risks.
Advertisement
Market Reaction
Knight Therapeutics' stock price fell to CA$9.31, reflecting a market cap of approximately CA$958 million. This decline may indicate a lack of confidence among investors, particularly in light of recent financial results and strategic moves.
Future Considerations
While Knight Therapeutics has shown promising growth with its recent Q3 2025 results, the stock's performance yesterday suggests that investors are weighing the risks associated with its acquisitions and overall market conditions. For those interested in the company's future, monitoring upcoming earnings calls and strategic announcements will be crucial.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
